Pozen enrolling for Phase III study of heart drug
Get the latest news alerts: Follow LTW at Twitter
Local Tech Wire
CHAPEL HILL, N.C. — Pozen Inc. (NASDAQ: POZN) said Friday that it has begun enrolling 1,000 patients across the country for two Phase III studies for its experimental drug for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
The compound, PA32540, is a fixed-dose combination of 325 mg of enteric-coated aspirin and 40 mg of immediate-release omeprazole.
The two trials will operate under a special protocol assessment that Pozen and the federal Food and Drug Administration set up, Pozen said. The studies will involve over 100 sites, enrolling approximately 500 patients per study.
“We believe that PA32540 could address the needs of certain patients with cardiovascular disease,” said Dr. John Fort, Pozen's chief medical officer.
Copyright 2012 WRAL Tech Wire. All rights reserved.
Featured
E-mail Preferences
The Skinny
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO
- Ignore Facebook hype - Check out 'risk factors,' too
- Facebook vs. Google IPO: Which deal ranks better?
- Triangle StartUp Factory says business already booming
- Entrepreneurship remains at heart of Tech Wire mission
- Flashback: Tech Wire launched 10 years ago today
- Silicon Valley's 'most provocative voice' - Former RTP exec Vivek Wadhwa